These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Drug development costs are overstated by the industry]. Jeppsson A Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545 [No Abstract] [Full Text] [Related]
27. Detective work: reading fine print, insurers question studies of drugs; Kaiser's veteran sleuth scours medical-journal articles and sees marketing spin; doctors fear loss of choices. Mathews AW Wall St J (East Ed); 2005 Aug; ():A1, A6. PubMed ID: 16222837 [No Abstract] [Full Text] [Related]
28. Albumin industry launches global promotion. Yamey G BMJ; 2000 Feb; 320(7234):533. PubMed ID: 10688548 [No Abstract] [Full Text] [Related]
29. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts. Brand R State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159 [No Abstract] [Full Text] [Related]
30. Drug samples are meant for advertising. Thawani V Issues Med Ethics; 2001; 9(3):91. PubMed ID: 16334483 [No Abstract] [Full Text] [Related]
31. [Drug industry is not to be subsidized by the society]. Melander A Lakartidningen; 2004 Feb; 101(7):613; author reply 613. PubMed ID: 15024879 [No Abstract] [Full Text] [Related]
32. Who bears the costs of antidepressants in Australia? Burrows GD; Norman TR Med J Aust; 1995 Feb; 162(3):162; author reply 164. PubMed ID: 7854232 [No Abstract] [Full Text] [Related]
34. Drug firms back-pedal on direct advertising. Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811 [No Abstract] [Full Text] [Related]
35. Supported by an unrestricted educational grant. Chepesiuk R CMAJ; 2003 Sep; 169(5):421-2. PubMed ID: 12952803 [No Abstract] [Full Text] [Related]
36. Who bears the costs of antidepressants in Australia? Tiller JW Med J Aust; 1995 Feb; 162(3):163; author reply 164. PubMed ID: 7854235 [No Abstract] [Full Text] [Related]
37. A world of hurt. Simons J Fortune; 2005 Jan; 151(1):17-8, 20. PubMed ID: 15696651 [No Abstract] [Full Text] [Related]
38. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886 [TBL] [Abstract][Full Text] [Related]
39. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Katon W; Cantrell CR; Sokol MC; Chiao E; Gdovin JM Arch Intern Med; 2005 Nov; 165(21):2497-503. PubMed ID: 16314547 [TBL] [Abstract][Full Text] [Related]
40. A new approach to drug development. Brown S N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099948 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]